PHILADELPHIA, PENNSYLVANIA — Neuromod Devices Ltd. has partnered with Treble Health to expand availability of Lenire, the only FDA-approved tinnitus treatment device of its kind, for Americans living with tinnitus in Philadelphia and Charlotte.
Tinnitus, commonly described as ringing, hissing, or buzzing in the ears, affects approximately 25 million American adults. It is estimated that 185,000 adults live with tinnitus in Philadelphia and 108,000 in Charlotte.
Treble Health is a hearing healthcare service specializing in tinnitus treatment and has treated more than 2,500 patients since its founding in 2020.
Recently, Treble Health expanded its care model by establishing a physical network of practices in Charlotte, Philadelphia, and other locations across the United States to complement its ongoing telehealth services.
This partnership ensures continued availability of Lenire to tinnitus patients through two Treble Health Network practices: Audiology & Hearing Services of Charlotte and The Tinnitus Treatment Center of Philadelphia.
Lenire treats tinnitus using bimodal neuromodulation, a therapy that simultaneously stimulates two nerves for therapeutic purposes.
The device delivers audio tones through headphones while providing mild energy pulses to the surface of the tongue. Under the supervision of an audiologist with tinnitus expertise, patients with bothersome tinnitus typically use the device at home for two 30-minute sessions daily for approximately 12 weeks.
“The Lenire device has been an outstanding addition to our tinnitus treatment options as clinicians,” said Dr. Gail Brenner Au. D., tinnitus specialist at The Tinnitus Treatment Center of Philadelphia. “It gives us another intervention that has proven to benefit the vast majority of tinnitus patients. I am delighted to make it available to my patients as part of Treble Health.”
The partnership follows publication of positive treatment outcomes from 140 U.S. patients in a real-world clinical setting in the American Journal of Audiology. 81.8% of patients with moderate or worse tinnitus demonstrated clinically significant improvement after approximately 12 weeks of treatment with Lenire.2,3
“I’m delighted to make Lenire available to tinnitus patients at these two Treble Health in-person clinics. Since Lenire’s De Novo approval by the US FDA in 2023 we have seen evidence of great treatment outcomes for patients be peer-reviewed and published in respected scientific journals. These results make it clear that Lenire is an extremely strong treatment option for tinnitus patients”, said Dr. Ben Thompson AuD, founder of Treble Health.
“Expanding the awareness and availability of Lenire to tinnitus patients in the USA and globally is a priority for Neuromod.” said Eric Timm, President, Global Commercial Operations & CEO, Neuromod USA Inc. “I’m delighted this partnership with Treble Health will give people living with tinnitus broader access to treatment with Lenire supported by guidance from expert clinicians.”
About Lenire®
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in large-scale clinical trials.
Bimodal neuromodulation is the stimulation of nerves with two paired stimuli for therapeutic purposes. The tinnitus treatment device used in the study, known as Lenire, was developed by Neuromod Devices.
It consists of wireless (Bluetooth®) headphones that deliver sequences of audio tones to both ears, combined with electrical stimulation pulses delivered to the surface of the tongue via 32 electrodes on a proprietary device trademarked as Tonguetip®. The device’s settings can be configured to provide treatment with different combinations of audio and electrical stimuli.
The timing, intensity, and delivery of the stimuli are controlled by an easy-to-use handheld controller that each participant is trained to use prior to continuing treatment at home. Patients with tinnitus are prescribed Lenire by an appropriately qualified healthcare professional, such as an Audiologist or ENT Surgeon, after an assessment for suitability and can complete treatment from home between follow-up appointments with their clinician.
Lenire® has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe and has received a De Novo Approval Grant by the US FDA.
About Treble Health
Treble Health is a specialized hearing healthcare company focused on the evaluation and treatment of tinnitus. Founded by brothers Dr. Ben Thompson, AuD and Dr. Garrett Thompson, AuD, Treble Health was established to provide evidence-based, personalized care for individuals experiencing bothersome tinnitus.
Since 2020, Treble Health has treated more than 2,500 patients with tinnitus across the United States. Care is delivered by licensed audiologists with advanced training in tinnitus management, using a comprehensive clinical approach that may include tinnitus retraining therapy, sound therapy, cognitive behavioral strategies, and emerging treatment technologies.
Treble Health operates in the United States and provides care through a national telehealth platform as well as select in-person clinics. This hybrid care model allows patients to access specialized tinnitus expertise regardless of geographic location.
References and Notes
- https://www.nidcd.nih.gov/health/tinnitus
- Kasper, C et al. Bimodal Neuromodulation for Tinnitus in a Clinical Practice Setting: Clinically Significant Benefit for Patients with Moderate or Worse Symptoms, American Journal of Audiology (2025). https://doi.org/10.1044/2025_AJA-25-00090
- As measured by Tinnitus Handicap Inventory (THI).
Source: Treble Health, Neuromod
